PRECISIONheor, Los Angeles, CA, USA.
GSK, Collegeville, PA, USA.
Antimicrob Resist Infect Control. 2022 Nov 4;11(1):133. doi: 10.1186/s13756-022-01170-3.
Although uncomplicated urinary tract infections (uUTIs; occurring in female patients without urological abnormalities or history of urological procedures or complicating comorbidities) are one of the most common community infections in the United States (US), limited data are available concerning associations between antibiotic resistance, suboptimal prescribing, and the economic burden of uUTI. We examined the prevalence of suboptimal antibiotic prescribing and antibiotic resistance and its effects on healthcare resource use and costs.
This retrospective cohort study utilized electronic health record data from a large Mid-Atlantic US integrated delivery network database, collected July 2016-March 2020. Female patients aged ≥ 12 years with a uUTI, who received ≥ 1 oral antibiotic treatment within ± 5 days of index uUTI diagnosis, and had ≥ 1 urine culture with antimicrobial susceptibility test, were eligible for inclusion in the study. The study examined the proportion of antibiotics that were inappropriately or suboptimally prescribed among patients with confirmed uUTI, and total healthcare costs (all-cause and UTI-related) within 6 months after a uUTI, stratified by antibiotic susceptibility and/or inappropriate or suboptimal treatment. Patient outcomes were assessed after 1:1 propensity score matching of patients with antibiotic-susceptible versus not-susceptible isolates and then by other covariates (e.g., demographics and recent healthcare use). A similar propensity score calculation was used to analyze the effect of inappropriate/suboptimal treatment on health outcomes. Costs were adjusted to 2020 US dollars ($).
Among 2565 patients with a uUTI included in the analysis, the most commonly prescribed antibiotics were nitrofurantoin (61%), trimethoprim-sulfamethoxazole (19%), and ciprofloxacin (15%). More than one-third of the sample (40.2%) had isolates that were not-susceptible to ≥ 1 antibiotic indicated for treating patients with uUTI. Two-thirds (66.6%) of study-eligible patients were prescribed appropriate treatment; 29.9% and 11.9% were prescribed suboptimal and/or inappropriate treatment, respectively. Inappropriate or suboptimally prescribed patients had greater all-cause and UTI-related costs compared with appropriately prescribed patients. Differences were most striking among patients with antibiotic not-susceptible isolates.
These findings highlight how the increasing prevalence of antibiotic resistance combined with suboptimal treatment of patients with uUTI increases the burden on healthcare systems. The finding underlines the need for improved prescribing accuracy by better understanding regional resistance rates and developing improved diagnostic tests.
尽管非复杂性尿路感染(UTI;发生于无尿路上异常或尿路上程序史或合并并存疾病的女性患者中)是美国(美国)最常见的社区感染之一,但关于抗生素耐药性、不适当处方和 UTI 经济负担之间的关联,数据有限。我们检查了不适当抗生素处方和抗生素耐药性的流行情况及其对医疗资源使用和成本的影响。
这是一项回顾性队列研究,利用来自美国中大西洋地区大型综合交付网络数据库的电子健康记录数据,数据收集时间为 2016 年 7 月至 2020 年 3 月。符合以下条件的年龄≥12 岁的女性 UTI 患者有资格入选本研究:患有 UTI,在 UTI 确诊后±5 天内接受了≥1 种口服抗生素治疗,且至少有 1 次尿液培养和抗菌药物敏感性试验。本研究检查了在确认患有 UTI 的患者中,抗生素的不适当或不适当处方的比例,以及 UTI 后 6 个月内(全因和 UTI 相关)的总医疗费用,按抗生素敏感性和/或不适当或不适当治疗进行分层。对抗生素敏感与非敏感分离株的患者进行 1:1 倾向评分匹配后,以及其他协变量(如人口统计学和近期医疗保健使用)评估患者结局。采用类似的倾向评分计算方法分析不适当/不适当治疗对健康结局的影响。将成本调整为 2020 年的美元($)。
在纳入分析的 2565 例 UTI 患者中,最常开的抗生素是呋喃妥因(61%)、复方磺胺甲噁唑(19%)和环丙沙星(15%)。超过三分之一(40.2%)的样本对≥1 种用于治疗 UTI 的抗生素耐药。研究中符合条件的患者中,有 66.6%的患者接受了适当的治疗;29.9%和 11.9%分别接受了不适当或不适当的治疗。与接受适当治疗的患者相比,不适当或不适当处方的患者的全因和 UTI 相关费用更高。在抗生素耐药的患者中,差异最为明显。
这些发现强调了抗生素耐药性的流行率增加以及 UTI 患者治疗的不适当治疗如何增加医疗系统的负担。研究结果强调需要通过更好地了解区域耐药率和开发改进的诊断测试来提高处方准确性。